Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Revefenacin Maintains Benefits Over 52 weeks

Key clinical point: Patients with COPD maintained respiratory improvements over 52 weeks on revefenacin, a recently approved once-daily bronchodilator.

Major finding: From 3 months until end of trial, all measured health status outcomes in all treatment arms improved at statistically significant levels (P < 0.05).

Study details: Randomized, parallel-group, 52-week trial of 1,055 patients with moderate to very severe COPD

Disclosures: The study was funded by Theravance Biopharma and Mylan.

Citation:

Donohue JF et al. Resp Res. 2019; 20:241.